The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Using enhanced ctDNA profiling to identify molecular determinants of response in R/R MCL
Leo Meriranta, MD, University of Helsinki, Helsinki, Finland, discusses a correlative study which used an enhanced ctDNA platform to determine treatment responses to lenalidomide, venetoclax and rituximab in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Dr Meriranta first discusses the Phase Ib/II VALERIA trial (NLG-MCL7; NCT03505944) from which patient samples were obtained, and then goes on to explain the value of analyzing ctDNA to better understand patient response to therapy. To conclude, Dr Meriranta shares some insights into the results obtained in this study. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
